TUM Antibody

What types of antibodies are most commonly used in TUM immunological research?

The Technical University of Munich (TUM) employs various antibody types in its immunological research, with selection based on specific research objectives. Chimeric antibodies containing human constant domains and mouse variable domains are frequently used in early-stage biotherapeutics research and diagnostic assay development due to their cost-effectiveness, batch-to-batch reproducibility, and homogeneous specificity and affinity . These antibodies reduce the risk of non-specific binding to heterophilic antibodies, such as human anti-mouse antibodies (HAMA), that can cause false positive assay results .

For therapeutic applications, humanized antibodies play a critical role, particularly when derived from non-human sources. The humanization process involves transferring critical non-human amino acids to human antibody frameworks to reduce immunogenicity in clinical applications . At TUM, researchers carefully evaluate each antibody type based on the specific experimental requirements and downstream applications.

How does TUM validate antibodies for experimental applications?

Antibody validation at TUM follows a systematic approach to ensure experimental reproducibility and reliability, addressing a critical need in the scientific community where up to 50% of studies face reproducibility challenges, with approximately 35% of these issues attributable to biological reagents like antibodies . The validation process encompasses:

• Sensitivity testing: Determining optimal dilution or concentration required to recognize the target antigen

• Specificity confirmation: Evaluating whether the antibody recognizes unintended targets in the sample

• Reproducibility assessment: Confirming consistent results across different methods or fixation protocols

For immunoblot analysis, TUM researchers provide comprehensive documentation including gel percentage used, sample preparation methods, and transfer protocols . Additionally, representative full blots are included as supplementary data to demonstrate protein specificity, with lanes clearly labeled to identify specific bands, nonspecific bands, and appropriate controls .

What methodological considerations should researchers make when selecting antibodies for different applications?

When selecting antibodies for research applications, several critical methodological considerations should be addressed:

Chimeric antibodies are particularly useful in early-stage research due to their reproducibility and homogeneous specificity . For critical targets, multiple antibodies recognizing different epitopes of the same protein may be compared to increase confidence in results. These methodological considerations significantly enhance experimental reliability and reproducibility, especially important for longitudinal studies like TUM's SARS-CoV-2 antibody research .

How is TUM employing DNA origami technology with antibodies for cancer immunotherapy?

TUM researchers have developed an innovative approach combining DNA nanotechnology with antibody engineering to create programmable T-cell engagers (PTEs). This groundbreaking methodology utilizes DNA origami, where self-folding DNA strands assemble into predetermined structures designed through computer simulation .

The experimental approach involves:

• Creating a chassis of folded DNA strands that serve as a structural framework

• Specifically attaching tumor-binding antibodies on one side of the DNA structure

• Mounting T-cell-recognizing antibodies on the opposite side

• Facilitating T-cell recruitment to destroy marked cancer cells

This system demonstrates remarkable efficacy, with in vitro testing showing more than 90% of cancer cells destroyed within 24 hours using optimized PTEs . The researchers produced and evaluated 105 different antibody combinations to determine optimal specificity for target cells and efficiency in recruiting T-cells.

The DNA origami platform offers significant advantages over traditional approaches:

• Precise spatial control of antibody positioning

• Ability to create virtually infinite combinations of antibody pairings

• Optimization potential for specific cancer types

• Highly targeted destruction of malignant cells while minimizing damage to healthy tissue

As noted by Dr. Adrian Gottschlich, one of the study's lead authors, "This approach permits us to produce all kinds of different PTEs and adapt them for optimized effects. Infinite combinations are in theory possible, making PTE a highly promising platform for treating cancer."

What computational models has TUM developed to understand antibody transport in tumor microenvironments?

TUM researchers have developed sophisticated computational diffusion models to simulate antibody transport within the tumor microenvironment (TME). This computational framework complements experimental 3D in vitro cancer models and employs light sheet fluorescence microscopy (LSFM) for real-time antibody tracking with high-resolution 3D imaging .

The computational model is based on the following principles:

• Assumption of purely diffusive antibody transport

• Consideration that binding sites on cell surfaces become saturated over time

• Combination of Fick's law with an exponential saturation equation

The mathematical model successfully described experimental antibody concentration profiles with high accuracy (within 5% RMSE), revealing that model parameters varied between cell clusters even at similar distances from the capsule periphery . This highlights the heterogeneity of antibody distribution within tumors.

Key findings from the model demonstrate:

This combined experimental and computational framework provides valuable insights for optimizing antibody delivery in cancer treatment and can be adapted to study different tumor cell lines and microenvironment components .

How is TUM conducting longitudinal SARS-CoV-2 antibody studies?

TUM's Klinikum rechts der Isar has implemented a comprehensive, longitudinal antibody study focusing on SARS-CoV-2. This prospective cohort study involves approximately 7,000 hospital employees who voluntarily participate in serological testing over a two-year period .

The methodological framework includes:

• Collection of blood samples from employees at the Klinikum rechts der Isar and associated scientific institutes

• Determination of specific antibody status for SARS-CoV-2

• Monitoring of antibody stability over the two-year study period

• Questionnaire-based assessment of infection risk exposure across different hospital areas (COVID-19 wards, normal wards, logistics, administration)

• Repeated testing at six-month intervals for a total of four examinations

Led by Professor Percy Knolle (Molecular Immunology) and Professor Paul Lingor (Neurological Clinic), the study aims to evaluate the duration of antibody-mediated protection after infection and assess the stability of specific immunity to SARS-CoV-2 over time . As Professor Knolle explained, "As we expect additional waves of the pandemic, the investigations will be conducted several times during its course... We will perform a total of four examinations every six months within a period of two years."

The study design allows researchers to compare antibody responses across different hospital departments with varying exposure risks, providing valuable insights into natural immunity development and maintenance while optimizing protective measures for patients and staff .

How are autoantibodies to tumor-associated antigens being utilized as biomarkers in TUM's cancer research?

TUM researchers are investigating autoantibodies against tumor-associated antigens (TAAs) as potential biomarkers for cancer detection and monitoring. This approach leverages the immune system's ability to recognize antigenic changes in cancer cells and develop autoantibodies against these altered cellular antigens .

The methodological approach includes:

• Detection of cancer-associated autoantibodies that act as "reporters" from the immune system

• Identification of antigenic changes in cellular proteins involved in the transformation process

• Utilization of these autoantibodies as biomarkers in cancer immunodiagnosis

The scientific rationale for this approach is particularly compelling because:

• These antibodies are generally absent or present in very low titers in normal individuals and non-cancer conditions, providing high specificity

• They demonstrate remarkable persistence and stability in the serum of cancer patients, unlike some tumor antigens themselves which may rapidly degrade or be cleared from circulation

• Detection methods and reagents for serum autoantibodies are widely available, facilitating characterization and assay development

This research direction holds significant promise for developing more sensitive and specific cancer detection methods, potentially enabling earlier intervention and improved patient outcomes through non-invasive blood tests .

What statistical approaches should be implemented when analyzing antibody-based experimental data?

When developing computational models for antibody transport, researchers should adjust parameters by minimizing the root mean square error between normalized experimental and computational profiles, as demonstrated in TUM's tumor microenvironment research where models achieved RMSE values up to 5% .

For longitudinal studies like the SARS-CoV-2 antibody research at Klinikum rechts der Isar, statistical approaches must account for within-subject correlations over time, allowing researchers to distinguish between biological changes and technical variation .

How should researchers address antibody batch variation in longitudinal studies?

Antibody batch variation presents a significant challenge in longitudinal studies that can compromise data comparability over time. Based on TUM research practices, the following methodological approaches are recommended:

• Bulk purchasing and aliquoting: When initiating long-term studies like the SARS-CoV-2 antibody research at Klinikum rechts der Isar, purchase sufficient antibody quantities from a single lot and create standardized aliquots stored under optimal conditions .

• Bridging protocols: When lot changes are unavoidable, perform bridging studies where samples are analyzed in parallel with both old and new antibody lots to establish conversion factors if necessary .

• Internal standards: Include consistent positive control samples in each experimental run to normalize for batch-to-batch variation. These controls often include recombinant proteins or well-characterized cell lysates .

• Comprehensive documentation: Meticulously record lot numbers, dilution factors, and incubation conditions for each experiment, allowing retrospective analysis of potential batch effects .

• Quality control metrics: Establish acceptance criteria for each assay, with experiments failing these criteria being excluded from analysis, regardless of whether the results support or contradict the research hypothesis .

For the two-year SARS-CoV-2 antibody study at Klinikum rechts der Isar with measurements every six months, these approaches are particularly important to ensure that observed changes in antibody levels reflect biological reality rather than technical artifacts .

What approaches enable multiplex antibody detection for simultaneous analysis of multiple targets?

Advanced multiplexing strategies allow for simultaneous detection of multiple targets using antibodies, enhancing information density while conserving valuable samples. Based on TUM research practices, the following methodological approaches are recommended:

The innovative DNA origami research at TUM demonstrates an advanced multiplexing concept, creating programmable T-cell engagers (PTEs) with different antibodies precisely positioned on a DNA scaffold to simultaneously engage tumor cells and T cells . This spatial multiplexing enables complex biological interactions that would be difficult to achieve with conventional methods.

When implementing multiplexed detection, careful validation is essential to ensure that each antibody maintains specificity and sensitivity when used in combination, and that signals can be reliably distinguished from one another .

What novel antibody reagents has TUM developed for studying the RAS signaling network?

TUM has contributed to the development of a comprehensive suite of antibody reagents specifically designed for studying the RAS signaling network, which is frequently implicated in cancer development. This effort aligns with the National Cancer Institute's RAS Initiative focused on understanding pathways and discovering therapies for RAS-driven cancers .

The antibody development and characterization methodology included:

• Generation of 104 monoclonal antibodies enabling detection of:

  • 27 phosphopeptides

  • 69 unmodified peptides

  • 20 proteins in the RAS network

• Rigorous validation following consensus principles developed by the broader research community

• Comprehensive application testing across multiple methodologies:

These antibody reagents were tested across diverse cell lines and tissue types, including MCF-10A, BxPC-3, NCI, A549, NCI-H1792, HeLa, and HEK293 cells, as well as breast, ovarian, colon, and lung tissues . All antibodies and characterization data are publicly available through the CPTAC Antibody Portal, Panorama Public Repository, and PRIDE databases, making them accessible to the wider research community for studying RAS signaling networks .

What guidelines should researchers follow for antibody validation in immunohistochemistry applications?

Immunohistochemistry (IHC) presents unique antibody validation challenges compared to other antibody-based methods. Based on research practices, the following comprehensive validation framework is recommended:

For publication, researchers should provide a representative full blot as supplemental data for each antibody, detailing the validation to demonstrate protein specificity. Lanes should be clearly labeled to note nonspecific and specific bands and positive and negative controls . This comprehensive validation approach ensures that IHC results are reliable and reproducible, addressing the particular challenges of detecting proteins in preserved tissue sections.

How is TUM applying computational modeling to optimize antibody diffusion in complex tissues?

TUM researchers have developed an integrated experimental-computational framework to track and simulate antibody transport within complex tissues. This approach combines 3D in vitro cancer models with light sheet fluorescence microscopy (LSFM) for real-time antibody tracking and computational modeling to predict antibody distribution .

The computational modeling methodology follows these steps:

• Development of a diffusion model based on Fick's law combined with an exponential saturation equation to account for binding site saturation

• Parameter adjustment by minimizing the root mean square error (RMSE) between normalized experimental and computational profiles

• Validation across multiple cell clusters to assess model accuracy in different microenvironmental contexts

• Extension to predict antibody distribution in modified microenvironments (e.g., with or without ECM fibers)

The model revealed important insights about antibody transport dynamics:

This computational approach enables researchers to predict how structural elements of the tissue microenvironment impact antibody penetration and distribution, with potential applications for optimizing therapeutic antibody delivery . The framework can be extended to study antibody transport in different tumor cell lines and additional microenvironment components, providing a powerful tool for rational design of antibody-based therapeutics.

What strategies is TUM employing to enhance antibody stability and tissue penetration?

Based on the search results, we can infer that TUM researchers are addressing antibody stability and tissue penetration challenges through several innovative approaches:

• Computational diffusion modeling: Developing sophisticated models to understand how structural elements of the tumor microenvironment affect antibody penetration and distribution, enabling rational design modifications to enhance tissue penetration .

• DNA origami technology: Creating programmable T-cell engagers (PTEs) with precise spatial control of antibody positioning, potentially allowing optimization of size, shape, and surface properties to improve tissue penetration while maintaining stability .

• Structure-guided engineering: Selecting appropriate antibody formats based on specific application requirements - from full-length antibodies for systemic applications to smaller fragments for enhanced tissue penetration .

• Antibody format selection: Utilizing chimeric antibodies containing human constant domains and mouse variable domains for early research, which offer batch-to-batch reproducibility and homogeneous specificity and affinity while reducing non-specific binding to heterophilic antibodies .

• Humanization processes: Implementing antibody humanization for therapeutic applications derived from non-human sources, which involves transferring critical non-human amino acids to human antibody frameworks to reduce immunogenicity while maintaining stability and function .

The computational modeling approach has particular significance for understanding and overcoming penetration barriers, as it revealed how ECM fibers can create heterogeneous antibody distribution patterns, with fibers perpendicular to the diffusion direction retaining antibodies and significantly reducing penetration to internal tissue regions .

How is TUM analyzing the stability and duration of SARS-CoV-2 antibody responses?

TUM's Klinikum rechts der Isar has implemented a comprehensive approach to analyze the stability and duration of SARS-CoV-2 antibody responses through a prospective cohort study involving approximately 7,000 hospital employees . The methodological framework includes:

• Longitudinal sampling design: Collection of blood samples at four timepoints over a two-year period, with examinations conducted every six months to track antibody kinetics over time .

• Risk stratification: Questionnaire-based assessment of infection risks that employees have been exposed to across different hospital areas (COVID-19 wards, normal wards, logistics, administration) to correlate exposure with antibody development and maintenance .

• Standardized serological testing: Determination of specific antibody status for SARS-CoV-2 using consistent methodologies across all timepoints to enable reliable comparison .

• Privacy-protected reporting: Communication of personally-identifiable results only to the employees themselves, while anonymized data is used for research purposes .

As Professor Percy Knolle, who leads the study alongside Professor Paul Lingor, explained: "The specific immunity to SARS-CoV-2 after surviving an infection will make it possible to estimate how long the antibodies can protect against renewed infection. At the present time, the data on this are still scarce worldwide."

The study aims to optimize protective measures for patients and staff in German hospitals while contributing valuable scientific insights into natural immunity development and maintenance following SARS-CoV-2 infection .

What innovative approaches is TUM developing for antibody-based cancer immunotherapy?

TUM researchers have developed a groundbreaking approach to cancer immunotherapy using DNA origami technology to create programmable T-cell engagers (PTEs). This innovative methodology represents a significant advancement in antibody-based cancer treatment .

The PTE development process involves:

• Creating a nano-chassis of folded DNA strands that serves as a structural framework

• Attaching tumor-binding antibodies on one side of the DNA structure

• Mounting T-cell-recognizing antibodies on the opposite side

• Facilitating T-cell recruitment to destroy marked cancer cells

The technical advantages of this approach include:

The researchers produced and tested 105 different antibody combinations, demonstrating remarkable efficacy with more than 90% of cancer cells destroyed within 24 hours using optimized PTEs . As noted by one of the study's lead authors, "This approach permits us to produce all kinds of different PTEs and adapt them for optimized effects. Infinite combinations are in theory possible, making PTE a highly promising platform for treating cancer."

This technology represents a significant advancement in the field of cancer immunotherapy, offering a highly customizable platform for developing targeted treatments with potential applications across multiple cancer types.